Navigation Links
Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B
Date:10/17/2011

OXFORD, England, October 18, 2011 /PRNewswire/ --

-- Third ocular product partnered with Sanofi approved to enter clinical development --

Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the Phase I/IIa clinical development of UshStat®, a novel gene-based treatment for Usher syndrome type 1B.  UshStat® was designed and developed by Oxford BioMedica using the Company's proprietary LentiVector® platform technology and is the third programme to enter clinical development under the Phase I/II ocular collaboration agreement signed with Sanofi in April 2009.

The approval of the IND follows the decision by the US Recombinant DNA Advisory Committee (RAC) to approve the UshStat® Phase I/IIa protocol in May 2011.  The open label, dose escalation Phase I/IIa study will enrol up to 18 patients with Usher syndrome type 1B at the Oregon Health and Science University's Casey Eye Institute, Portland, Oregon.  The study, led by Professor Richard Weleber, will evaluate three dose levels for safety, tolerability and aspects of biological activity and is expected to be initiated by the end of 2011.

Usher syndrome is the most common form of deaf-blindness which affects approximately 30,000-50,000 patients in the US and Europe.  One of the most common subtypes is Usher syndrome type 1B.  The disease is caused by a mutation of the gene encoding myosin VIIA (MY07A), which leads to progressive retinitis pigmentosa combined with a congenital hearing defect.  UshStat® uses the Company's LentiVector® platform technology to deliver a corrected version of the MYO7A gene to address the vision loss associated with the disease.  O
'/>"/>

SOURCE Oxford BioMedica plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
2. Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb
3. Oxford Finance Corporation Sponsors 2010 Mid-Atlantic Bio
4. Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio
5. Oxford Finance Corporation Hires Dr. Killu Sanborn to Support Life Science Business Development in Western North America
6. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
7. Oxford BioTherapeutics Appoints Michael Moore as Chairman
8. Oxford Performance Materials Introduces OXPEKK PermettaTM High Performance Polymer Films
9. TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford
10. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
11. Bavarian Nordics Case Against Oxford BioMedica
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Earlier this month, a report was created by ... Air Force on the performance of vehicles using an ... of fuel made from mustard seeds, offered great potential ... Eco friendly future. In fact, every branch of the ... of foreign oil over the next few years. They ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Supplementing ... offering a promotion for Eppendorf Safe Lock ... to purchase the highest quality tubes at an ... ideal for customers doing chemical, medical, pharmaceutical, and ... who are not regularly able to afford Eppendorf ...
(Date:8/27/2014)... Salt Lake City, Utah (PRWEB) August 27, 2014 ... new construction that will expand its current Salt Lake ... operations currently underway outside of Utah to ultimately create ... the next 20 years. , “Utah is home ... many of whom can be credited with Varian’s success ...
(Date:8/27/2014)... 27, 2014 Rhythm, a biopharmaceutical company developing ... that result in metabolic disorders, announced today that it ... the U.S. Securities and Exchange Commission (SEC) relating to ... common stock. The number of shares to be offered ... yet been determined. Citigroup and Cowen and ...
Breaking Biology Technology:Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2
... VENTURA, Calif., Dec. 12 VivoMetrics Inc., a ... the,appointment of Howard R. Baker to the position ... Paul Kennedy, who will remain with,the company in ... Baker joins VivoMetrics with over 28 years in ...
... Oral Iclaprim, "Rolling" NDA for Intravenous Iclaprim in cSSSI; Electronic ... First Modules ... Arpida Ltd,(SWX: ARPN) announced today the enrolment and dosing of ... iclaprim in the treatment,of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia,(VAP) ...
... for the First Time on 50 mg/Day Dose for PRISTIQ ... Treatment of ... a division of Wyeth (NYSE: WYE ), announces that ... serotonin-norepinephrine reuptake inhibitor (SNRI), showed,that adult patients who received a ...
Cached Biology Technology:VivoMetrics(R) Appoints Howard R. Baker as New President and Chief Executive Officer 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 3First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 4First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6
(Date:8/31/2014)... CAMBRIDGE, MA -- Over the past several decades, malaria diagnosis ... a patient, a technician smears the blood across a glass ... a microscope for the Plasmodium parasite, which causes the disease. ... are in the blood an important measure of disease ... for human error. , A research team from the Singapore-MIT ...
(Date:8/29/2014)... surprising discoveries about the body,s initial responses to ... team found that specialized cells in the intestine ... invasion and are the source of gut inflammation ... , Though aimed at the presence of ... that provides a barrier to protect the body ...
(Date:8/29/2014)... Until recently, little has been known about what ... international team of scientists, one of whom is a ... by showing that genes controlling the development of the ... rabbit domestication., The study was published Aug. 28 in ... questions. It is online at http://www.sciencemag.org/ ., The ...
Breaking Biology News(10 mins):A new way to diagnose malaria 2A new way to diagnose malaria 3The early cost of HIV 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... Rome, Italy: Scientists have discovered that when they ... not only does the procedure make the mice fertile ... their lifespan. The question now is: could ovarian transplants ... Kagawa will tell the 26th annual meeting of the ...
... chemistry sets, ham radio, amateur astronomy, and early computing? ... Today, over 2,000 people from around the world belong ... from microbial fuel cells, low-cost lab equipment, environmental surveillance, ... Synthetic Biology Project at the Woodrow Wilson Center is ...
... WEST LAFAYETTE, Ind. - A Purdue University researcher has found ... their shelf life by about a week. Avtar Handa, ... increases production of a compound that slows aging and delays ... the early online version of The Plant Journal , ...
Cached Biology News:Ovarian transplantation restores fertility to old mice and also lengthens their lives 2Ovarian transplantation restores fertility to old mice and also lengthens their lives 3Gene leads to longer shelf life for tomatoes, possibly other fruits 2
... cyclin required for G1-phase progression and is ... cyclin D2 can phosphorylate pRB when associated ... Human, Mouse, and Rat. Others-not tested. ... suited for neutralization of cyclin D2 activity ...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
... Synthetic peptide corresponding ... Antigen Family: ... Antigen Subfamily: not ... Recommended Storage: Long ...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: